Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency

Transfusion

Volumn 51, Issue 10, 2011, Pages 2237-2243

  Terrell, Deirdra R ^a,b,c   Motto, David G ^a,b,c   Kremer Hovinga, Johanna A ^a,b,c   Lämmle, Bernhard ^a,b,c   George, James N ^a,b,c   Vesely, Sara K ^a,b,c  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD GROUP O; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME DEFICIENCY; ETHNICITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGRO; RACE DIFFERENCE; RISK FACTOR; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ABO BLOOD-GROUP SYSTEM; ADAM PROTEINS; ADOLESCENT; ADULT; AFRICAN AMERICANS; AGE FACTORS; AGED; ASIAN AMERICANS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; INDIANS, NORTH AMERICAN; MALE; MIDDLE AGED; OKLAHOMA; PROSPECTIVE STUDIES; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RISK FACTORS; SEX FACTORS; YOUNG ADULT;

EID: 80054735804     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2011.03125.x     Document Type: Article

References (25)

1. Staropoli JF, Stowell CP, Tuncer HH, Marques MB,. An inquiry into the relationship between ABO blood group and thrombotic thrombocytopenic purpura. Vox Sang 2009; 96: 344-8.
2. Zuberi L, Yerasuri D, Kuriakose P,. Effect of blood group on idiopathic thrombotic thrombocytopenic purpura. J Clin Apheresis 2009; 24: 131-3.
3. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR,. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69: 1691-5. (Pubitemid 17091627)
4. Shimia M, Fujimura Y, Nishiyama T, Tsujuichi T, Narita N, Matsui T, Titani K, Katayama M, Fumi-ichiro Y, Yoshioka A,. ABO blood group genotype and plasma von Willebrand factor in normal individuals. Vox Sang 1995; 68: 236-40.
5. Miller CH, Haff E, Platt SJ, Rawlins P, Drews CD, Dilley AB, Evatt B,. Measurement of von Willebrand factor activity: relative effects of ABO blood type and race. J Thromb Haemost 2003; 1: 2191-7.
6. O'Donnell JS, McKinnon TA, Crawley JTB, Lane DA, Laffan MA,. Bombay phenotype is associated with reduced plasma VWF levels and an increased susceptibility to ADAMTS13 proteolysis. Blood 2005; 106: 1988-91. (Pubitemid 41291710)
7. Gallinaro L, Cattini MG, Szlukowska M, Padrini R, Sartorello F, Pontara E, Bertomoro A, Daidone V, Pagnan A, Casonato A,. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 2008; 111: 3540-5.
8. Bowen DJ,. The influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost 2003; 1: 33-40.
9. Mannucci PM, Capoferri C, Canciani MT,. Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease. Br J Haematol 2004; 126: 213-8. (Pubitemid 38961940)
10. Moake JL,. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-600.
11. Wu O, Bayoumi N, Vickers MA, Clark P,. ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. J Thromb Haemost 2008; 6: 62-9.
12. Wiggins KL, Smith NL, Glazer NL, Rosendaal FR, Heckbert SR, Psaty BM, Rice KM, Lumley T,. ABO genotype and risk of thrombotic events and hemorrhagic stroke. J Thromb Haemost 2009; 7: 263-9.
13. Vesely SK, George JN, Lämmle B, Studt JD, Alberio L, El-Harake MA, Raskob GE,. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 101: 60-8. (Pubitemid 36759636)
14. Kremer Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN,. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115: 1500-11.
15. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lämmle B,. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-84. (Pubitemid 28536132)
16. Bianchi V, Robles R, Alberio L, Furlan M, Lämmle B,. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002; 100: 710-3. (Pubitemid 34761143)
17. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T,. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129: 93-100. (Pubitemid 40524057)
18. Kremer Hovinga JA, Mottini M, Lämmle B,. Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods. J Thromb Haemost 2006; 4: 1146-8.
19. Tripodi A, Peyvandi F, Chantarangkul V, Palla R, Afrasiabi M, Canciani MT, Chung DW, Ferrari S, Fujimura Y, Karimi M, Kokame K, Kremer Hovinga JA, Lämmle B, de Meyer SF, Plaimauer B, Vanhoorelbeke K, Varadi K, Mannucci PM,. Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). J Thromb Haemost 2008; 6: 1534-41.
20. Garratty G, Glynn SA, McEntire R,. ABO and Rh(D) phenotype frequencies of different racial/ethnic groups in the United States. Transfusion 2004; 44: 703-6. (Pubitemid 38608247)
21. Terrell DR, Williams LA, Vesely SK, Lammle B, Kremer Hovinga JA, George JN,. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS13 deficiency. J Thromb Haemost 2005; 3: 1432-6. (Pubitemid 41725200)
22. Terrell DR, Vesely SK, Kremer Hovinga JA, Lämmle B, George JN,. Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes. Am J Hematol 2010; 85: 844-7.
23. Hsieh MM, Everhart JE, Byrd-Holt DD, Tisdale JF, Rodgers GP,. Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences. Ann Intern Med 2007; 146: 486-92. (Pubitemid 351650557)
24. Raife TJ, Cao W, Atkinson BS, Bedell B, Montgomery RR, Lentz SR, Johnson GF, Zheng XL,. Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site. Blood 2009; 114: 1666-74.
25. Motto DG, Chauhan AK, Zhu G, Homeister J, Lamb DB, Desch KC, Zhang W, Tsai HM, Wagner DD, Ginsburg D,. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest 2005; 115: 2752-61. (Pubitemid 41434402)